DavidRizzieriMDCPE

Oncology • Charlotte, NC

Hematologic Oncology

System Physician Executive Senior Vice President Novant Health Cancer Institute

Join to view full profile

Dr. Rizzieri is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rizzieri's full profile

Already have an account?

Office
125 Queens Rd Ste 610
Charlotte, NC 28204
Phone+1 980-302-6600

Fax+1 980-302-6605

Summary

I focused on clinical research in hematologic malignancies and transplantation until accepting the role as SVP for Novant Cancer Institute in NC where we are focused on advancing cancer care in the state providing an exceptional patient experience through disease specialists working in multiD fashion to offer the most current therapies, including novel clinical trials.

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1994 - 1997
University of RochesterResidency, Internal Medicine, 1991 - 1994
University of Rochester School of Medicine and DentistryClass of 1991
Hobart CollegeBS, General Biology, Summa Cum Laude, 1983 - 1987

Certifications & Licensure

NC State Medical License 1997 - 2025
NY State Medical License 1993 - 1994
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Agnes B and Edward I Weisiger Endowed Chair of Cancer Research Novant Health, 2023
Wendell Ross teaching award Duke Univ, 2012
NCI team leader award NCI, 2010
Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Elected Member The American Society for Clinical Investigation, 2009
Senior Science Award Hobart College, 1987
Melvin J Shapiro Scholarship for excellence in Natural Sciences Hobart College, 1985
Phi Beta Kappa Hobart College
Sigma Xi Hobart College
President's Scholarship Hobart College
Dean's List Hobart College
Athletic Club's "Junior Varsity" Hobart College
Join now to see all

Clinical Trials

Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia Start of enrollment: 2002 May 01
Completed
Phase 2
Sorafenib in Myelodysplastic Syndrome Start of enrollment: 2006 Jul 01
Terminated
Phase 2
Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma Start of enrollment: 2007 Jan 01
Terminated
Phase 2
PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma Start of enrollment: 2005 Nov 01
Terminated
Phase 2
DepoCyt for Active Lymphomatous or Leukemic Meningitis Start of enrollment: 2006 Jun 01
Terminated
Phase 2
Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma Start of enrollment: 2005 Jun 18
Completed
Phase 2
Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath Start of enrollment: 2005 May 01
Completed
Phase 2
Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath Start of enrollment: 2003 Feb 01
Completed
Phase 2
Safety Trial of NK DLI From 6/6 HLA Matched Family Member Following Nonmyeloablative ASCT Start of enrollment: 2005 May 01
Completed
Phase 1
Safety Trial of NK Cell DLI 3-5/6 Family Member Following Nonmyeloablative ASCT Start of enrollment: 2005 Apr 01
Completed
Phase 1
Intensive Induction Therapy Followed by High Dose Chemo and BM Transplant for Mantle Cell Lymphoma Start of enrollment: 1998 Feb 01
Completed
Phase 2
Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant Start of enrollment: 2008 Feb 01
Completed
Phase 2
EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2008 Feb 01
Terminated
Phase 2
Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML Start of enrollment: 2009 Oct 01
Completed
Phase 2
A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia Start of enrollment: 2009 Dec 01
Completed
Phase 2
Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML) Start of enrollment: 2010 Jun 01
Completed
Phase 3
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting Start of enrollment: 2010 Dec 02
Completed
Trial of CMV Specific DLIs From 3-6/6 HLA Matched Family Member Following Nonmyeloablative Allo SCT Start of enrollment: 2011 Feb 01
Terminated
Phase 1
Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant Start of enrollment: 2011 Dec 01
Completed
Phase 1, Phase 2
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
Completed
Phase 3
Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2012 Jan 01
Completed
Phase 1
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Start of enrollment: 2012 Sep 01
Completed
Phase 1
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Start of enrollment: 2012 Dec 14
Completed
Phase 1
Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant Start of enrollment: 2013 Aug 01
Completed
L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBL Start of enrollment: 2013 Oct 01
Terminated
Phase 1
Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia Start of enrollment: 2012 Apr 01
Terminated
Phase 1, Phase 2
SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia Start of enrollment: 2014 Sep 01
Completed
Phase 1, Phase 2
Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma Start of enrollment: 2018 Apr 04
Terminated
Phase 1
Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL Start of enrollment: 2022 Jan 01
Withdrawn
Phase 2
Join now to see all

Publications & Presentations

PubMed

658 citations
Hematopoietic Engraftment and Survival in Adult Recipients of Umbilical-Cord Blood from Unrelated Donors
Mary J. Laughlin, Juliet N. Barker, Barbara Bambach, Omer N. Koc, David A. Rizzieri
The New England Journal of Medicine. 2001-06-14
88 citations
Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Rese...
Carla Casulo, Jonathan W. Friedberg, Kwang Woo Ahn, Christopher R. Flowers, Alyssa DiGilio
Biology of Blood and Marrow Transplantation. 2018-06-01
28 citations
Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia
Tod A. Morris, Carlos M. DeCastro, Louis F. Diehl, Jon P. Gockerman, Anand S. Lagoo
Leukemia Research. 2013-01-01

Journal Articles

MDS: unraveling the mystery
Rizzieri DA, Blood, 12/1/2013
The genetic landscape of mutations in Burkitt lymphoma
Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH, Choi WW, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers CR, ..., Nat Genet, 11/1/2012
Phase II Study of Cenersen, an Antisense Inhibitor of p53, in Combination with Fludarabine, Cyclophosphamide, and Rituximab for High Risk CLL
Lanasa MC, Davis PH, Datto M, Li Z, Gockerman JP, Moore JO, Decastro CM, Friedman DR, Diehl LF, Rehder C, Cook H, Daugherty FJ, Matta KM, Weinberg JB, Rizzieri D, Leuk Lymphoma, 2/1/2012
Chemoimmunotherapy’s potential to impact paroxysmal nocturnal hemoglobinuria
Rizzieri DA, Walsh K, Clin Adv Hematol Oncol, 1/1/2012
Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia
O'Brien S, Rizzieri DA, Vey N, Ravandi F, Krug UO, Sekeres MA, Dennis M, Venditti A, Berry DA, Jacobsen TF, Staudacher K, Bergeland T, Giles FJ, Br J Haematol, 1/1/2012
MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia
Giles FJ, Swords RT, Nagler A, Hochhaus A, Ottmann OG, Rizzieri DA, Talpaz M, Clark J, Watson P, Xiao A, Zhao B, Bergstrom D, Le Coutre PD, Freedman SJ, Cortes JE, Leukemia, 1/1/2012
Leukemic Stem Cells, A Review
Jenny O’Brien, David Rizzieri, Cancer Investigation, 1/1/2012
Elacytarabine,a novel 5’-claidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia
Giles F, Rizzieri D, Ravandi F, Swords R, Jacobsen TF, O'Brien S, Leuk Res, 1/1/2012
Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning
Kanda J, Rizzieri DA, Gasparetto C, Long GD, Chute JP, Sullivan KM, Morris A, Smith CA, Hogge DE, Nitta J, Song K, Niedzwiecki D, Chao NJ, Horwitz ME, Biol Blood Marrow Transplant, 6/1/2011
Early Pre/Post Transplant Fluoro-Deoxyglucose Positive Emission Tomography (FDG-PET) does predict outcome for patients undergoing hematopoietic stem cell transplantati...
J. Palmer, T. Goggins, G. Broadwater, N.Chao, G. Long, M. Horwitz, A. Beavens, J. Chute, K. Sullivan, C. Gasparetto, E. Coleman, D. Rizzieri, Bil Blood and Marrow Trns, 1/1/2011
Renal Shielding and Dosimetry for Patients with Severe Systemic Sclerosis Receiving Immunoablation with Total Body Irradiation in the Scleroderma: Cyclophosphamide or ...
Craciunescu OI, Steffey BA, Kelsey CR, Larrier NA, Paarz-Largay CJ, Prosnitz RG, Chao N, Chute J, Gasparetto C, Horwitz M, Long G, Rizzieri D, Sullivan KM, Int J Radiat Oncol Biol Phys, 1/1/2011
Donor cell-derived leukemias/myelodysplastic neoplasms in allogeneic hematopoietic stem cell transplant recipients: a clinicopathologic study of 10 cases and a compreh...
Wang E, Hutchinson CB, Huang Q, Lu CM, Crow J, Wang FF, Sebastian S, Rehder C, Lagoo A, Horwitz M, Rizzieri D, Yu J, Goodman B, Datto M, Buckley P, Am J Clin Pathol, 1/1/2011
Histone H4 acetylation by immunohistochemistry and prognosis in relapsed acute lymphocytic leukaemia (ALL)
Advani AS, Gibson S, Douglas E, Diacovo J, Elson P, Kalaycio M, Copelan E, Sekeres M, Sobecks R, Sungren S, Lagoo A, Rizzieri D, Hsi E, Br J Haematol, 1/1/2011
Alemtuzumab for the prevention and treatment of graft-versus-host disease
Kanda J, Lopez RD, Rizzieri DA, Int J Hematol, 1/1/2011
Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismat...
Rizzieri DA, Crout C, Storms R, Golob J, Long GD, Gasparetto C, Sullivan KM, Horwitz M, Chute J, Lagoo AS, Morris A, Beaven A, Yang Y, Peterson B, Li Z, Chao NJ, Cancer Invest, 1/1/2011
Severe Pulmonary Toxicity After Myeloablative Conditioning Using Total Body Irradiation: An Assessment of Risk Factors
Kelsey CR, Horwitz ME, Chino JP, Craciunescu O, Steffey B, Folz RJ, Chao NJ, Rizzieri DA, Marks LB, Int J Radiat Oncol Biol Phys, 1/1/2011
Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia
Rizzieri D, LoRusso S, Tse W, Khan K, Advani A, Moore J, Karsten V, Cahill A, Gerson SL, Clin Lymphoma Myeloma Leuk, 6/1/2010
Haploidentical transplantation for leukemia
Kanda J, Chao NJ, Rizzieri DA, Curr Oncol Rep, 1/1/2010
Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure
Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM, Kamble R, Copelan E, de Lima M, Gupta V, Keating A, Lazarus HM, Litzow MR, Marks DI, Maziarz RT, Rizzieri DA, Sc..., J Clin Oncol, 1/1/2010
Comparable survival after hla-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogeneti...
Vikas Gupta, Martin S Tallman, Wensheng He, Brent R Logan, Edward A Copelan, Robert Peter Gale, Hanna J. Khoury, Thomas Klumpp, John Koreth, Hillard M Lazarus, David I..., Blood, 1/1/2010
Overcoming Drug Resistance in Mantle Cell Lymphoma Using a Combination of Dose Dense and Intense Therapy
Christopher A. Crout, Liang-Piu Koh, Jon P. Gockerman, Joseph O. Moore, Carlos DeCastro, Gwynn D. Long, Louis Diehl, Christina Gasparetto, Donna Niedzwiecki, Jon Edwar..., Cancer Invest, 1/1/2010
Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia
Rizzieri DA, O'Brien JA, Broadwater G, Decastro CM, Dev P, Diehl L, Beaven A, Lagoo A, Gockerman JP, Chao NJ, Moore JO, Cancer, 1/1/2009
Hedgehog signaling is essential for maintenance of cancer stem cells in myeloid leukaemia
Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, Blum J, Kwon HY, Kim J, Chute JP, Rizzieri D, Munchhof M, Vanarsdale T, Beachy PA, Reya T, Nature, 1/1/2009
Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors
Rizzieri DA, Dev P, Long GD, Gasparetto C, Sullivan KM, Horwitz M, Chute J, Chao NJ, Bone Marrow Transplant, 1/1/2009
Apolipoprotein E genotype as a determinant of survival in CLL
Weinberg J, Volkheimer A, Mihovilovic M, Jian N, Chen Y, Bond K, Moore J, Gockerman J, Diehl L, DeCastro C, Rizzieri D, Levesque M, DeKroon R, Strittmatter W, Leukemia, 1/1/2008
Join now to see all

Abstracts/Posters

Geriatric Assessment Identifies Impairments in Younger Candidates for Allogeneic Hematopoietic Stem Cell Transplantation
David A. Rizzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory AnalysisClinically Relevan...
David A. Rizzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic ...
David A. Rizzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Te...
David A. Rizzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart¬ Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
David A. Rizzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Single-Cell RNA-Seq Identifies Potentially Pathogenic B Cell Populations That Uniquely Circulate in Patients with Chronic Gvhd
David A. Rizzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase I Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Blastic Plasmacytoid Dendriti...
David A. Rizzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Daily Chlorhexidine Gluconate Bathing Reduces the Rate of Bloodstream Infections in Adults Undergoing Inpatient Hematopoietic Stem Cell Transplantation
David A. Rizzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Biomarker Modulation By Mivebresib (ABBV-075) +/_ Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia
David A. Rizzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Evaluation of the Oral SYK Inhibitor Fostamatinib in Patients after Allogeneic Transplantation for Chronic Graft-Versus-Host Disease
David A. Rizzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Decreased Mortality after the First Year of Allogeneic Hematopoietic Stem Cell Transplant in Recipients of Umbilical Cord Blood Vs. Matched Related or Matched Unrelate...
David A. Rizzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

A Phase 2 Study of Actinium-225 (225Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
ET190L1-ARTEMISTM T Cell Therapy Results in Durable Disease Remissions with No Cytokine Release Syndrome or Neurotoxicity in Patients with Relapsed and Refractory B-Ce...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observati...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

21 Recent Hospital, Health System Executive MovesOctober 1st, 2021
Chutes & Ladders—MD Anderson Names First Chief Data Officer; HHS Appoints Civil Rights DirectorSeptember 30th, 2021
'i Expect Excellence in Everything We Do': New Executive for Novant Health’s Cancer Institute Outlines His GoalsSeptember 29th, 2021
Join now to see all